Clinical status and research progress of immunotherapy resistance in lung cancer
10.12354/j.issn.1000-8179.2024.20240601
- VernacularTitle:肺癌免疫治疗耐药的临床现状与研究进展
- Author:
Xu FAN
1
;
Liu YAO
;
Yang YUN
;
Luo BIN
;
Tian JIANHUI
Author Information
1. 上海中医药大学附属市中医医院肿瘤临床医学中心(上海市 200071);上海中医药大学附属市中医医院肿瘤研究所
- Keywords:
lung cancer;
immuno-resistance;
mechanisms of drug resistance;
coping strategies
- From:
Chinese Journal of Clinical Oncology
2024;51(12):628-634
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the malignant tumor with the highest incidence and lethality globally.In recent years,emerging immunotherapy based on the immune checkpoint inhibitors,programmed cell death protein-1 and its ligand(PD-1/L1),as a representative,has made revolu-tionary breakthroughs in the field of lung cancer.The indications for this treatment mode have moved from driver-gene-negative advanced or locally advanced lung cancer to adjuvant and neoadjuvant treatment of perioperative lung cancer,and an increasing number of mono-clonal antibodies against PD-1 and PD-L1 has been approved for the treatment of lung cancer.However,with the widespread use of immun-otherapy,the problem of drug resistance has gradually come to the fore.Only a small proportion of the overall lung cancer population re-sponds to immunotherapy,bringing a new round of challenges to lung cancer treatment.In this paper,the clinical status of immunotherapy resistance in lung caner is reviewed,and cutting-edge advances in knowledge of resistance mechanisms and coping strategies are reviewed,with the aim of providing clinicians with ideas and the basis for formulating individualized,precise treatment plans.
